Biosimulytics Enters Exclusive HPC Cloud Partnership with CGG to Accelerate Market Adoption of its AI Drug Development Technology
Biosimulytics, an Irish pharma software company, today announced that it has signed an exclusive partnership agreement with CGG, a global technology and HPC leader headquartered in Paris, France.
CGG will provide Biosimulytics, which uses artificial intelligence (AI) technologies to dramatically improve drug development, with a fully customized HPC (high performance computing), AI, and cloud solution to rapidly serve the company’s growing volume of pharmaceutical customers worldwide.
Using CGG’s algorithm and HPC expertise enables Biosimulytics to fully scale its breakthrough pharmatech platform which provides pharmaceutical companies with a powerful predictive simulation capability when developing new drug molecules.
The Biosimulytics technology shortens the time to market and reduces the risks for important developments in the pharmaceutical industry in getting from molecules to medicine (M2M) and is a key enabling technology for the new era of precision medicine.
CGG’s custom solution meets the specialist needs of Biosimulytics for a high-performing HPC and AI environment that optimizes its suite of specialized molecular simulation applications from crystal structure prediction (CSP) to structure-based drug design (SBDD).
Biosimulytics can now run applications at least five times faster than its previous public cloud solution, enabling it to dramatically improve its return on investment and rapidly expand its business.
As a European company offering cloud services hosted in the European Union, CGG also offers the full legal protection of EU regulations for the intellectual property of Biosimulytics and its customers.
Biosimulytics, which is headquartered at NovaUCD in Dublin, is a University College Dublin (UCD) spin-out company from the UCD School of Chemical and Bioprocess Engineering that was founded in 2019.
Biosimulytics is also an Enterprise Ireland High-Potential Start-Up (HPSU) company and is strongly backed at the European level through EIT Digital and other EU-funded accelerator programmes.
Biosimulytics is working as a Digital R&D solution provider to some of the world’s leading pharmaceutical companies. The AI drug development market is expected to exceed US$10bn by 2030 growing at a CAGR of 25%.
Peter Doyle, CEO and co-founder, Biosimulytics
Peter Doyle, CEO and Co-Founder of Biosimulytics, said, “We are delighted to announce this exclusive partnership with CGG since our need for a high-performing HPC and AI environment to optimize our Biosim M2M platform is uniquely met with CGG's customized solution.
The AI drug development space is now at an inflection point and our ambition is to enable the global pharma industry to advance potential molecules to approved medicines quicker and with a much greater probability of success by making AI-powered predictive technology much more accessible and affordable for widespread use by everyone from Big Pharma to small emerging biotech companies. Today’s announcement with CGG is a significant milestone on that journey.”
Agnès Boudot, EVP, HPC & Cloud Solutions, CGG, said, “CGG is a global expert in industrial and customized end-to-end HPC and AI services with over 70 years of experience in pioneering computing solutions. After successfully establishing our cloud services offering in the energy, energy transition and mining sectors, where more than 30 external clients are currently directly accessing and using CGG Cloud solution services for delivering insights into their data, we are pleased to expand into the healthcare and life sciences market by supporting Biosimulytics in using AI- and HPC-based technologies to help unlock new and improved therapies faster and more cost efficiently.
Our experience of hosting and optimizing scientific workflows running on over 350 petaflops at an industrial scale ensures that we can provide Biosimulytics with a scalable solution to meet their future growth requirements for this complex HPC and AI workflow.”
ENDS
4 May 2023
For further information contact Micéal Whelan, Communications and Media Relations Manager, UCD Research and Innovation, e: miceal.whelan@ucd.ie or Paul Kilroy-Glynn, Head of Business Development, Biosimulytics, e: pkilroyglynn@biosimulytics.ai.
Editors Notes
Biosimulytics (www.biosimulytics.ai) is a fast-growing university spinout company providing a quantum physics-based, AI/ML-powered pharmatech platform that leverages the powerful predictive capabilities of the company’s proprietary software and patent-protected algorithms. Based in Dublin Ireland, the company serves the global pharmaceutical industry in deploying its technology to improve the speed, scale, novelty and success rate of drug development in getting from molecules to medicine (M2M).